GlassScriptPhysician profile
Michael K Shaheen
NPI 1659504173
$94,458.39
in general payments reported to CMS, 2019-2025
21 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,144 · 2020: $733 · 2021: $3,519 · 2022: $17K · 2023: $20K · 2024: $27K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Travel and Lodging: $18K · Consulting Fee: $15K · Food and Beverage: $5,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,278.00 |
| Travel and Lodging | $17,690.47 |
| Consulting Fee | $15,142.50 |
| Food and Beverage | $5,615.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $89,359.34 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Biofinity Contact Lens |
| Alcon Vision LLC | $1,036.89 | 2019-2025 | Precision 1, Dailies Total1, Total30 |
| Abb Con-Cise Optical Group LLC | $996.99 | 2019-2025 | Spectacle Lenses, Contact Lens |
| Johnson & Johnson Vision Care, INC. | $664.04 | 2019-2024 | |
| Sight Sciences, INC. | $437.83 | 2024-2025 | Tearcare System |
| Bausch & Lomb Americas INC. | $421.40 | 2022-2025 | Infuse, Infuse Multifocal |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $293.12 | 2019-2021 | |
| Ivantis, INC | $201.82 | 2019-2021 | |
| Shire North American Group INC | $180.03 | 2019 | |
| Kala Pharmaceuticals, INC. | $144.66 | 2021-2022 | |
| Amgen INC. | $130.01 | 2024 | Tepezza |
| Optos, INC. | $116.85 | 2019 | |
| Lkc Technologies, INC. | $96.59 | 2025 | |
| Sun Pharmaceutical Industries INC. | $83.74 | 2019-2022 | |
| Abbvie INC. | $73.03 | 2022-2023 | Lumigan, Vuity, Alphagan P |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $61.54 | 2022-2025 | Tyrvaya, Ryzumvi |
| Vantage Technology LLC | $43.83 | 2023 | |
| Novartis Pharmaceuticals Corporation | $39.64 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $37.66 | 2025 | Austedo Xr |
| Allergan, INC. | $19.98 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shaheen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.